But why do you want to do this global stuff?

Yeah, so you may be able to glean from my name.

I'm of Indian origin, and I come from kind of a legacy of a family that has been in medicine or public health.

And I spent childhoods every summer, the entire summer, being in India practicing.

And I think was exposed very early to just the tremendous disparities of healthcare.

And I think had family members that, you know, spent their lives to trying to close that equity gap.

So I think for me, it was a little bit just what I always saw and knew.

And how do you go about in your work Or how would you recommend we go about understanding or getting to understand what those local barriers and issues are, the cultural barriers, the way that health systems established? What is your process? How do you go through that?

So can you tell us a little bit about CIRCULATE?

Yeah.

So I mean, just to level set a little bit, circulating tumor DNA in colorectal cancer, and actually across many solid tumors, has Really emerged as one of the most powerful and strongest prognostic biomarkers.

So time and time again, it really trumps any T-staging, nodal staging, and particularly in stage two colorectal cancer where this study has been evaluating the use of ctDNA, multiple studies that have shown ctDNA being highly prognostic with hazard ratios nearly reaching twenty or twenty-plus in some study sets.

And what we've seen to date is that observational data has suggested there may be benefit from adjuvant chemotherapy in ctDNA-positive patients.

But no study to date has actually read out positive to actually show that the use of adjuvant chemotherapy in a stage two patient population changes outcomes.

By way of other background, the current stage two largest data was out of Australia and was a dynamic study, and dynamic didn't look at actually guiding treatment escalation.

Why don't we move on to adjuvant therapy in colon cancer with aspirin? So I'd love to hear your thoughts on the EPISODE study.